查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1862965

體外肺模型市場：依模型類型、應用、細胞來源、技術、產品類型和最終用戶分類－2025-2032年全球預測

In Vitro Lung Model Market by Model Type, Application, Cell Source, Technology, Product Type, End Users - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，體外肺模型市場規模將達到 25.0275 億美元，複合年成長率為 17.48%。

關鍵市場統計數據
基準年 2024 6.8938億美元
預計年份：2025年 8.1258億美元
預測年份 2032 2,502,750,000 美元
複合年成長率 (%) 17.48%

科學和監管的共同推動，正將體外肺模型發展成為核心的臨床前資產，從而重塑轉化和商業化策略。

呼吸系統研究和臨床前試驗領域正經歷顯著的變革時期，這主要得益於科學技術的進步、監管機構對與人體相關的模型日益重視，以及減少動物試驗依賴的迫切需求。體外肺模型，包括2D培養、3D類器官、晶片器官平台和精密切片組織，正與細胞來源、微加工和生物工程領域的創新相結合，為疾病建模和藥物測試提供更具預測性和擴充性的替代方案。這種融合正在重塑研究人員檢驗作用機制、篩檢候選藥物和評估呼吸毒性的方式。

在慢性肺病和急性肺病領域持續存在未被滿足的需求之際，製藥和生物技術開發商正加速推進呼吸系統藥物研發管線，而這些進展也正是在此背景下湧現。同時，監管機構和倫理監督機構對支持安全性和有效性聲明的人體相關數據提出了更高的要求。這些促進因素共同作用，正推動體外肺模型從專業的學術工具轉變為轉化研究策略的核心組成部分。本導言概述了技術、監管和商業性因素如何相互作用，重新定義臨床前階段可靠性和可擴充性方面的預期，為後續的深入專題分析奠定了基礎。

技術整合和跨部門合作正在將客製化的體外肺部實驗轉變為可擴展、檢驗的平台，從而指導監管和商業性進程。

體外肺模型領域正從孤立的概念驗證實驗轉型為支持藥物發現、開發和監管互動決策的整合平台。微流體、支架工程和幹細胞分化技術的成熟使得所建構的模型更真實地模擬肺泡和支氣管的微環境、細胞異質性和動態力學作用。這使得研究人員能夠以更高的生理保真度探索疾病機制，並測試從小分子藥物到生物製藥和細胞療法等各種治療方法，從而提高其臨床應用價值。

隨著技術進步，學術界、產業界和受託研究機構(CRO) 之間的合作正在加速模型標準化、可重複性研究以及與臨床終點的交叉檢驗。這些合作透過建立共用通訊協定和品質標準，降低了模型應用的門檻。此外，整合高內涵成像、多體學數據和人工智慧驅動分析的數位化增強技術提高了體外實驗的可解釋性，並能夠更詳細地分析細胞反應的表現型。這些變革正將體外肺模型從客製化的實驗工具轉變為可擴展、檢驗的平台，並可納入監管策略和商業開發流程。

關稅政策引起的供應鏈變化可能會促使籌資策略重組，並促進體外肺模型材料的本地化生產。

關稅政策的變化會影響設計、製造、分銷和採購體外肺模型技術和試劑的機構的營運決策。影響進口實驗室設備、微流體組件和​​專用生物試劑的貿易措施可能會改變採購計畫和單位經濟效益，尤其對於依賴跨境供應鏈的研究團隊和公司而言更是如此。如果關稅增加關鍵材料的到岸成本，機構可能需要考慮短期調整措施，例如尋找替代供應商、提前採購或本地生產，以維持實驗的連續性。

除了直接的成本影響外，關稅驅動的供應鏈變化可能會加速生產和分銷網路的戰略本地化。企業可能會尋求加強與區域供應商的關係，或投資於國內製造能力，以減輕關稅波動的影響。同時，受託研究機構和研究機構可能會擴大供應商範圍，納入受關稅影響較小的市場的供應商，並優先考慮能夠緩衝成本突發波動的庫存管理策略。隨著時間的推移，這些調整可能會影響研發中心和專業製造群的分佈，進而影響區域競爭格局以及先進體外肺模型技術的獲取途徑。

多層細分框架揭示了模型類型、應用領域、電池來源、技術、產品類型和最終用戶需求如何匯聚，從而塑造採用趨勢和策略重點。

在體外肺模型領域，建立精細的市場區隔框架對於理解客戶需求、技術適用性和實際效用至關重要。依模型類型分類，市場涵蓋2D細胞培養、3D器官、晶片肺系統和精密切割肺切片。2D細胞培養可進一步區分細胞株和原代細胞培養，這反映了二者在通量、生理相關性和獲取複雜性上的差異。3D類器官則分為肺泡類器官和支氣管類器官，分別滿足不同的疾病建模和藥物反應分析需求。基於應用領域的細分可以明確最終用途，例如疾病建模、藥物發現與開發、個人化醫療和毒性測試，並將特定的實驗目標與最佳模型類別連結起來。細胞來源分析則區分了動物性細胞、細胞株和人源性細胞。人源細胞進一步細分為原代細胞和幹細胞衍生細胞，這一分類對轉化應用和監管合規性有顯著影響。基於技術的分類重點在於微流體技術、支架培養和無支架培養。微流體系統進一步分為連續流系統和液滴系統，支架培養又分為天然支架和合成支架，無支架培養則分為生物反應器和懸滴培養。每種選擇都代表著複雜性、擴充性和生理模擬性之間的權衡。產品類型著重於儀器和試劑套件/試劑，最終用戶涵蓋學術研究機構、受託研究機構(CRO)、製藥和生物技術公司以及監管機構。將這些細分市場與客戶優先事項結合，可以揭示生理保真度、通量、成本效益和監管相容性等方面的需求趨同或分歧之處，從而幫助平台提供者識別策略機遇，最佳化其針對不同使用者群體的價值提案。

區域生態系統和政策框架導致美洲、歐洲、中東和非洲以及亞太地區體外肺模型的應用模式存在差異。

區域趨勢影響人才、資本、法規結構和製造生態系統的獲取，而這些都對體外肺模型的開發和應用至關重要。美洲擁有高度集中的轉化研究中心、生物技術叢集和受託研究機構（CRO），這有利於新型平台的快速部署，並促進學術研究人員和商業開發人員之間的合作。該地區的法規環境和支付方結構也推動了對與人體相關的模型的需求，這些模型可以縮短開發週期並降低後期失敗的風險。

在歐洲、中東和非洲地區，嚴格的監管要求、倫理框架以及強大的產學合作共同促進了嚴謹的模型檢驗和統一標準的發展。公私合營以及對轉化研究中心的投資支持了跨國技術擴散，而重點國家的國家戰略則優先加強先進生物工程能力。在亞太地區，產能的快速擴張、大規模生產能力以及不斷完善的臨床研究基礎設施，使該地區成為體外肺模型技術的重要生產和消費區域。政府支持的創新計畫和不斷壯大的生物技術人才庫也在推動區域市場成長，為本地生產和大規模應用創造了有利環境。

市場領先的公司正在建立一個平台生態系統，該生態系統整合了設計模型、標準化通訊協定和數位分析，以降低採用門檻並提高轉換研究的可靠性。

體外肺模型領域的競爭格局呈現出技術供應商、設備製造商、試劑開發商和服務型合約檢驗受託研究機構（ CRO）並存的局面。主要企業正致力於打造兼具卓越技術和生物學保真度的平台能力，許多企業也透過策略聯盟尋求轉化驗證和市場拓展。將模組化硬體與靈活的試劑套件相結合的企業更有可能吸引更廣泛的終端用戶，因為它們降低了實驗的技術門檻，同時支援高級應用客製化。

市場領導的一個顯著趨勢是尋求將模型平台與數位分析和標準化通訊協定相結合的生態系統策略。這些策略透過解決可重複性問題並簡化從藥物發現到臨床前測試的工作流程中的資料整合，降低了准入門檻。此外，積極與監管機構和標準化聯盟合作的公司可以透過塑造檢驗範式和明確產品申報的證據要件而獲得優勢。對於新參與企業而言，針對特定疾病領域或測試方案中未被滿足的需求的利基能力——例如專用類器官系、專有支架化學或獨特的微流體架構——通常是其差異化優勢的來源。擁有技術專長和可擴展營運能力的服務供應商仍然是尋求外包複雜檢測並加快結果獲取速度的機構的重要合作夥伴。

應優先考慮交叉檢驗、模組化產品設計、策略合作、本地採購數位資料整合，以推動產品採用並降低營運風險。

產業領導者應優先考慮加快檢驗、擴大可及性，並使平台開發與監管和臨床證據要求保持一致。首先，應投資進行交叉驗證研究，將體外模型輸出與特徵明確的臨床終點和已建立的體內基準進行比較，以增強轉化相關性的論點。其次，應開發模組化產品套件，提供清晰的升級路徑，將支援高通量篩檢的基礎配置與能夠為後期研究提供更高生理複雜性的高階模組相結合。第三，應加強與合約研究機構和學術機構的合作，建構共用的檢驗資料集，並擴大對最終用戶的技術支援。

同時，企業應盡可能實現供應鏈環節本地化，以降低關稅風險並縮短關鍵零件的前置作業時間。建立以最佳實踐、數據解讀和監管要求為重點的客戶教育項目，將有助於降低採用門檻並增強市場信心。最後，投資於數位化分析和標準化資料格式，將使客戶能夠把體外實驗結果與多體學和臨床資料集整合，從而透過清晰的決策路徑和下游商業化途徑，增強模型採用的商業價值。

我們採用透明且多角度的調查方法，結合專家訪談、同儕審查證據、監管文件和情境分析，以支持我們可靠的見解和建議。

本報告整合了定性訪談、二手文獻以及結構化的技術檢驗框架，以得出平衡且可重複的分析結果。主要資料來源包括與學術界、受託研究機構和商業領域的科學家、研發負責人和採購專業人員進行深入討論，以了解買方需求、技術挑戰和檢驗預期。次要資料來源包括同行評審出版物、監管指導文件、專利概況和公司披露資訊，以確定技術藍圖和實用化證據。

我們的分析方法結合了技術比較評估和基於情境的供應鏈分析，以評估採購和政策變數（包括關稅和區域製造能力）對採用趨勢和策略定位的影響。我們的細分市場映射方法採用屬性驅動的方法，將模型類型、應用、電池來源和技術與用戶優先級和證據要求相匹配。在整個研究過程中，我們強調三角驗證和透明度：所有論點均有多重資料輸入支持，方法論假設均有記錄，並且在證據不確定的領域中明確闡述了局限性。這種方法確保了我們的結論和建議建立在充分論證的基礎上，結合了技術見解、相關人員的觀點和可觀察的市場行為。

要實現其轉化潛力，嚴格的檢驗、支持性的生態系統和策略性的商業化對於將體外肺模型的進展轉化為持續的臨床和商業性價值至關重要。

體外肺模型正從研究熱點轉變為基礎工具，對藥物發現、安全性評估和轉化決策有重大影響。微流體、人工支架和幹細胞生物學等技術的融合，使得建構生理保真度更高的模型成為可能；同時，數據分析技術的進步也為深入解讀細胞反應提供了可能。這些進展，加上不斷變化的監管要求和策略性供應鏈重組，意味著能夠將檢驗的體外數據整合到研發流程中的企業，將在降低臨床專案風險和縮短產品上市時間方面獲得競爭優勢。

採用情況不會一成不變，而是會因細分市場和區域趨勢的不同而有所差異。投資於檢驗、標準化和客戶支援的公司將加快並擴大採用範圍。同樣重要的是，策略性地關注採購韌性和夥伴關係生態系統將有助於減輕外部衝擊，並為更廣泛的實施創造可擴展的路徑。總之，為了將技術可能性轉化為組織能力，我們強調相關人員必須將科學創新與嚴格的檢驗、周全的商業性包裝以及與監管機構和標準制定機構的積極合作相結合。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合機械刺激的晶片器官微流體肺模型的研究進展
  • 將個人化呼吸系統疾病模型與患者來源的肺類器官結合
  • 利用3D生物列印技術建構高保真血管化肺組織
  • 利用人工智慧驅動成像和高內涵篩檢進行體外肺毒性測試
  • 開發一種能夠模擬機械拉伸和氣流模式的動態晶片肺系統
  • 新冠病毒研究中對包含上皮細胞、內皮細胞和免疫細胞的共培養肺模型的需求日益成長
  • 推出利用先進體外肺部暴露技術的新型氣溶膠藥物傳遞測試平台
  • 推進標準化和監管途徑，以期在毒性測試中接受體外肺模型數據。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 體外肺模型市場（依模型類型分類）

  • 2D細胞培養
    • 細胞株培養
    • 原代細胞培養
  • 3D類器官
    • 肺泡類器官
    • 支氣管類器官
  • 晶片肺
  • 精準切割的肺片

9. 體外肺模型市場（依應用分類）

  • 疾病模型
  • 藥物發現與開發
  • 個人化醫療
  • 毒性測試

10. 體外肺模型市場（依細胞來源分類）

  • 動物源性細胞
  • 細胞株
  • 人類來源細胞
    • 原代細胞
    • 幹細胞衍生細胞

11. 依技術分類的體外肺模型市場

  • 微流體技術
    • 連續流系統
    • 滴灌系統
  • 基於支架的培養
    • 天然支架
    • 合成支架
  • 無支架培養
    • 生物反應器
    • 懸垂

12. 體外肺模型市場（依產品類型分類）

  • 裝置
  • 套件和試劑

13. 體外肺模型市場（依最終用戶分類）

  • 學術和研究機構
  • CRO
  • 製藥和生物技術公司
  • 監管機構

14. 體外肺模型市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

15. 體外肺模型市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國體外肺部模型市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Emulate, Inc.
    • MIMETAS BV
    • CN Bio Innovations Ltd.
    • Hurel Corporation
    • TissUse GmbH
    • Epithelix Sarl
    • MatTek Life Sciences, Inc.
    • InSphero AG
    • Kirkstall Ltd
    • Stemina Biomarker Discovery, Inc.
Product Code: MRR-F6513A06BD96

The In Vitro Lung Model Market is projected to grow by USD 2,502.75 million at a CAGR of 17.48% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 689.38 million
Estimated Year [2025] USD 812.58 million
Forecast Year [2032] USD 2,502.75 million
CAGR (%) 17.48%

A converging scientific and regulatory momentum is elevating in vitro lung models into central preclinical assets that reshape translational and commercial strategies

The landscape of respiratory research and preclinical testing is experiencing a profound transformation driven by scientific advances, regulatory emphasis on human-relevant models, and a growing imperative to reduce reliance on animal studies. In vitro lung models-encompassing two-dimensional cultures, three-dimensional organoids, organ-on-chip platforms, and precision-cut tissue slices-are converging with innovations in cellular sourcing, microfabrication, and bioengineering to offer increasingly predictive and scalable alternatives for disease modeling and drug testing. This convergence is reshaping how researchers validate mechanisms of action, screen therapeutic candidates, and assess respiratory toxicology.

These advances come at a moment when pharmaceutical and biotechnology developers are accelerating respiratory pipelines in response to persistent unmet needs across chronic and acute pulmonary conditions. Simultaneously, regulatory agencies and ethical oversight bodies are signaling stronger expectations for human-relevant data to support safety and efficacy claims. Together, these drivers are elevating in vitro lung models from specialized academic tools to core components of translational research strategies. The introduction outlines how the interplay of technological, regulatory, and commercial forces is redefining expectations for preclinical confidence and operational scalability, and sets the stage for the deeper thematic analysis that follows.

Technological integration and cross-sector collaboration are converting bespoke in vitro lung experiments into scalable, validated platforms that inform regulatory and commercial pathways

The in vitro lung model landscape is shifting from isolated proof-of-concept experiments toward integrated platforms that can feed decision-making across discovery, development, and regulatory interaction. Technological maturation in microfluidics, scaffold engineering, and stem cell differentiation is enabling models that better recapitulate alveolar and bronchial microenvironments, cellular heterogeneity, and dynamic mechanical forces. As a result, researchers can explore disease mechanisms at greater physiological fidelity and test modalities ranging from small molecules to biologics and cell therapies with improved translational relevance.

Parallel to technological progress, partnerships between academia, industry, and contract research organizations are accelerating model standardization, reproducibility studies, and cross-validation against clinical endpoints. These collaborations are reducing barriers to adoption by establishing shared protocols and quality benchmarks. In addition, digital augmentation-integrating high-content imaging, multi-omics readouts, and AI-driven analytics-is amplifying the interpretative power of in vitro assays and enabling more granular phenotyping of cellular responses. Collectively, these shifts are transforming in vitro lung models from bespoke experimental tools into scalable, validated platforms that can be incorporated into regulatory strategies and commercial development pathways.

Tariff-driven supply chain shifts can reshape procurement strategies and incentivize regional manufacturing localization for in vitro lung model inputs

Tariff policy changes can influence the operational calculus for organizations that design, manufacture, distribute, or source in vitro lung model technologies and reagents. Trade measures that affect imported laboratory instruments, microfluidic components, or specialized biological reagents can alter procurement timelines and unit economics, particularly for research groups and companies reliant on cross-border supply chains. When tariffs increase the landed cost of critical inputs, organizations must evaluate near-term adjustments such as alternative suppliers, forward buying, or localized manufacturing to preserve experimental continuity.

Beyond direct cost impacts, tariff-induced supply chain shifts can accelerate strategic localization of production and distribution networks. Firms may seek to deepen regional supplier relationships or invest in domestic manufacturing capabilities to reduce exposure to tariff volatility. In parallel, contract research organizations and research institutions may broaden their vendor base to include suppliers from tariff-insulated markets, and prioritize inventory management strategies that buffer against abrupt cost changes. Over time, these adaptations can influence where R&D centers and specialized manufacturing clusters concentrate, shaping regional competitive dynamics and access to advanced in vitro lung model capabilities.

A layered segmentation framework reveals how model type, application, cell source, technology, product type, and end-user needs converge to shape adoption and strategic priorities

A nuanced segmentation framework is essential for understanding customer needs, technology fit, and translational utility across the in vitro lung model landscape. When considering model type, the market spans 2D cell cultures, 3D organoids, lung-on-a-chip systems, and precision-cut lung slices. Within 2D cell cultures, a further distinction exists between cell line cultures and primary cell cultures, reflecting differences in throughput, physiological relevance, and sourcing complexity. The 3D organoid category separates into alveolar organoids and bronchial organoids, each serving discrete disease modeling and drug-response interrogation needs. Application-driven distinctions clarify end use across disease modeling, drug discovery and development, personalized medicine, and toxicity testing, linking specific experimental objectives to the most appropriate model class. Cell source analysis differentiates animal-derived cells, cell lines, and human-derived cells; human-derived cells are subdivided into primary cells and stem cell-derived cells, a split with strong implications for translational relevance and regulatory acceptability. Technology-based segmentation highlights microfluidics, scaffold-based cultures, and scaffold-free cultures; microfluidic systems are further categorized into continuous flow systems and droplet-based systems, scaffold-based cultures divide into natural and synthetic scaffold approaches, and scaffold-free cultures separate into bioreactor and hanging drop modalities, each choice signaling trade-offs between complexity, scalability, and physiological mimicry. Product type focuses attention on instruments versus kits and reagents, and end users span academic and research institutes, contract research organizations, pharmaceutical and biotechnology companies, and regulatory agencies. Mapping these segments against customer priorities reveals where demand for physiological fidelity, throughput, cost-efficiency, and regulatory alignment converge or diverge, and it helps identify strategic opportunities for platform providers to tailor value propositions to distinct user cohorts.

Regional ecosystems and policy frameworks are driving differentiated adoption patterns for in vitro lung models across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics influence access to talent, capital, regulatory frameworks, and manufacturing ecosystems that underpin the development and deployment of in vitro lung models. In the Americas, there is a concentration of translational research centers, biotech clusters, and contract research organizations that support rapid adoption of novel platforms and facilitate partnerships between academic innovators and commercial developers. The regulatory environment and payer landscapes in this region also drive demand for human-relevant models that can accelerate development timelines and de-risk late-stage failures.

Across Europe, the Middle East & Africa, the interplay of stringent regulatory expectations, ethical frameworks, and strong academic-industrial linkages promotes rigorous model validation and harmonized standards. Investment in public-private collaborations and translational research hubs supports cross-border technology diffusion, while national strategies in key countries prioritize advanced bioengineering capabilities. In the Asia-Pacific region, rapid capacity expansion, substantial manufacturing capabilities, and a growing base of clinical research infrastructure position the area as a critical producer and consumer of in vitro lung model technologies. Local market growth is also stimulated by government-backed innovation programs and an expanding biotechnology talent pool, creating fertile conditions for both localized production and large-scale adoption.

Market leaders are building integrated platform ecosystems that combine engineered models, standardized protocols, and digital analytics to reduce adoption friction and enhance translational credibility

Competitive dynamics in the in vitro lung model domain reflect a mix of specialized technology providers, instrument manufacturers, reagent developers, and service-oriented contract research organizations. Leading companies are investing in platform capabilities that blend engineering excellence with biological fidelity, and many are pursuing strategic partnerships to expand translational validation and market reach. Firms that combine modular hardware with flexible reagent suites tend to appeal to a broader set of end users because they lower technical barriers to experimentation while enabling customization for advanced applications.

An observable trend among market leaders is the pursuit of ecosystem plays that integrate model platforms with digital analytics and standardized protocols. These strategies reduce friction for adoption by addressing reproducibility concerns and by simplifying data integration across discovery and preclinical workflows. Additionally, companies that actively engage with regulatory bodies and standard-setting consortia gain an advantage by shaping validation paradigms and clarifying evidentiary expectations for product submissions. For newer entrants, differentiation often stems from niche capabilities-such as specialized organoid lines, unique scaffold chemistries, or proprietary microfluidic architectures-that address unmet needs in specific disease areas or testing regimes. Service providers that combine technical expertise with scalable operations remain key partners for organizations seeking to outsource complex assays or to accelerate time to result.

Prioritize cross-validation, modular product design, strategic partnerships, localized sourcing, and digital data integration to accelerate adoption and mitigate operational risks

Industry leaders should prioritize actions that accelerate validation, broaden accessibility, and align platform development with regulatory and clinical evidence needs. First, invest in cross-validation studies that compare in vitro model outputs with well-characterized clinical endpoints and established in vivo benchmarks to strengthen claims of translational relevance. Second, develop modular product suites that offer clear upgrade paths: basic configurations that support high-throughput screening alongside advanced modules that deliver enhanced physiological complexity for late-stage testing. Third, expand partnerships with contract research organizations and academic centers to create shared validation datasets and to scale technical support for end users.

Concurrently, companies should localize supply chain elements where feasible to mitigate tariff risk and to shorten lead times for critical components. Building customer education programs focused on best practices, data interpretation, and regulatory expectations will reduce barriers to adoption and foster market trust. Finally, invest in digital analytics and standardized data formats that enable customers to integrate in vitro outputs with multi-omics and clinical datasets, thereby amplifying the business case for model adoption through clearer pathways to decision-making and downstream commercialization.

A transparent, triangulated methodology combining expert interviews, peer-reviewed evidence, regulatory documents, and scenario analysis to support defensible insights and recommendations

This report synthesizes qualitative interviews, secondary literature, and a structured framework of technical validation to generate a balanced and reproducible analysis. Primary inputs included in-depth discussions with scientists, R&D leaders, and procurement specialists across academic, contract research, and commercial settings to capture buyer requirements, technical pain points, and validation expectations. Secondary sources comprised peer-reviewed publications, regulatory guidance documents, patent landscapes, and company disclosures that illuminate technology roadmaps and translational evidence.

Analytical methods combined comparative technology assessment with scenario-based supply chain analysis to evaluate how procurement and policy variables, including tariffs and regional manufacturing capacity, could influence adoption and strategic positioning. Segment mapping followed an attribute-driven approach that aligns model types, applications, cell sources, and technologies with user priorities and evidence requirements. Throughout the research process, emphasis was placed on triangulation and transparency: assertions are corroborated across multiple data inputs, methodological assumptions are documented, and limitations are acknowledged where evidence remains emergent. This approach ensures that conclusions and recommendations rest on a defensible blend of technical insight, stakeholder perspectives, and observable market behaviors.

Translational promise requires rigorous validation, supportive ecosystems, and strategic commercialization to convert in vitro lung model advances into sustained clinical and commercial value

In vitro lung models are transitioning from research curiosities to foundational tools that can materially influence discovery, safety assessment, and translational decision-making. Technological convergence across microfluidics, engineered scaffolds, and stem cell biology is enabling models with greater physiological fidelity, while improvements in data analytics are unlocking richer interpretations of cellular responses. These advances, coupled with evolving regulatory expectations and strategic supply chain realignments, mean that organizations able to integrate validated in vitro data into development workflows will gain a competitive advantage in de-risking clinical programs and accelerating go-to-market timelines.

Adoption will not be uniform; instead, it will reflect the nuances captured in segmentation and regional dynamics. Companies that invest in validation, standardization, and customer support will increase the speed and breadth of uptake. Equally important, strategic attention to procurement resilience and partnership ecosystems will mitigate external shocks and create scaleable pathways for broader implementation. The conclusion underscores a pragmatic imperative: to translate technological promise into organizational capability, stakeholders must pair scientific innovation with rigorous validation, thoughtful commercial packaging, and proactive engagement with regulatory and standards-setting communities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in organ-on-chip microfluidic lung models with integrated mechanical stimulation
  • 5.2. Integration of patient-derived lung organoids for personalized respiratory disease modeling
  • 5.3. Use of 3D bioprinting techniques to create vascularized lung tissue constructs with high fidelity
  • 5.4. Application of AI-driven imaging and high-content screening in in vitro lung toxicity assays
  • 5.5. Development of dynamic lung-on-chip systems simulating mechanical stretch and airflow patterns
  • 5.6. Growing demand for co-culture lung models incorporating epithelial, endothelial, and immune cells for COVID-19 research
  • 5.7. Emerging aerosolized drug delivery testing platforms using advanced in vitro lung exposures
  • 5.8. Standardization and regulatory pathways evolving for acceptance of in vitro lung model data in toxicity testing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In Vitro Lung Model Market, by Model Type

  • 8.1. 2D Cell Cultures
    • 8.1.1. Cell Line Cultures
    • 8.1.2. Primary Cell Cultures
  • 8.2. 3D Organoids
    • 8.2.1. Alveolar Organoids
    • 8.2.2. Bronchial Organoids
  • 8.3. Lung-On-A-Chip
  • 8.4. Precision-Cut Lung Slices

9. In Vitro Lung Model Market, by Application

  • 9.1. Disease Modeling
  • 9.2. Drug Discovery & Development
  • 9.3. Personalized Medicine
  • 9.4. Toxicity Testing

10. In Vitro Lung Model Market, by Cell Source

  • 10.1. Animal-Derived Cells
  • 10.2. Cell Lines
  • 10.3. Human-Derived Cells
    • 10.3.1. Primary Cells
    • 10.3.2. Stem Cell-Derived Cells

11. In Vitro Lung Model Market, by Technology

  • 11.1. Microfluidics
    • 11.1.1. Continuous Flow Systems
    • 11.1.2. Droplet-Based Systems
  • 11.2. Scaffold-Based Cultures
    • 11.2.1. Natural Scaffolds
    • 11.2.2. Synthetic Scaffolds
  • 11.3. Scaffold-Free Cultures
    • 11.3.1. Bioreactors
    • 11.3.2. Hanging Drop

12. In Vitro Lung Model Market, by Product Type

  • 12.1. Instruments
  • 12.2. Kits & Reagents

13. In Vitro Lung Model Market, by End Users

  • 13.1. Academic & Research Institutes
  • 13.2. CROs
  • 13.3. Pharmaceutical & Biotechnology Companies
  • 13.4. Regulatory Agencies

14. In Vitro Lung Model Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. In Vitro Lung Model Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. In Vitro Lung Model Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Emulate, Inc.
    • 17.3.2. MIMETAS B.V.
    • 17.3.3. CN Bio Innovations Ltd.
    • 17.3.4. Hurel Corporation
    • 17.3.5. TissUse GmbH
    • 17.3.6. Epithelix Sarl
    • 17.3.7. MatTek Life Sciences, Inc.
    • 17.3.8. InSphero AG
    • 17.3.9. Kirkstall Ltd
    • 17.3.10. Stemina Biomarker Discovery, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. IN VITRO LUNG MODEL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. IN VITRO LUNG MODEL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. IN VITRO LUNG MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2